Kairos Pharma, Ltd.
KAPA
$0.85
-$0.01-1.05%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 121.36% | 108.78% | 57.59% | 17.89% | 153.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 182.84% | 141.43% | 76.91% | 36.41% | 146.09% |
| Operating Income | -182.84% | -141.43% | -76.91% | -36.41% | -146.09% |
| Income Before Tax | -84.68% | -134.85% | -78.08% | -43.65% | -207.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.68% | -134.85% | -78.08% | -43.65% | -207.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.68% | -134.85% | -78.08% | -43.65% | -207.98% |
| EBIT | -182.84% | -141.43% | -76.91% | -36.41% | -146.09% |
| EBITDA | -198.90% | -154.55% | -84.08% | -40.15% | -182.33% |
| EPS Basic | -18.57% | -73.46% | -43.68% | -29.14% | -198.26% |
| Normalized Basic EPS | -35.95% | -96.82% | -67.14% | -54.80% | -197.77% |
| EPS Diluted | -18.57% | -73.46% | -43.68% | -29.14% | -198.26% |
| Normalized Diluted EPS | -35.95% | -96.82% | -67.14% | -54.80% | -197.77% |
| Average Basic Shares Outstanding | 56.67% | 36.68% | 21.50% | 9.37% | 2.96% |
| Average Diluted Shares Outstanding | 56.67% | 36.68% | 21.50% | 9.37% | 2.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |